健康教育视频：呼吸训练器（三球仪）的使用方法

字号 + –

04 9月 2019

1
2
3
4
5

Author : 伤口世界

原创：中诺医疗中诺医疗

呼吸训练器（三球仪）是集阻力呼吸、缩唇呼吸、容量锻炼和耐力训练于一体的训练工具，适用于对抗衰老、预防和治疗疾病，如心、胸、腹、盆部等手术前后、机械通气后、ICU、脑损伤神经肌肉功能障碍、面瘫、吞咽功能障碍、长期吸烟、COPD、胸廓畸形和长期卧床等。呼吸训练器（三球仪）在国外发达国家普遍使用。

主要禁忌症为不稳定型冠心病、近期出现的心肌梗死、学习认知能力障碍及精神疾病。肺大泡和气胸应控制好通气量，避免过度呼吸。

中诺医疗（QQ：2040056692，联系电话：0551-67732172）根据十多年的临床教育经验，总结出呼吸训练器（三球仪）的八个要素：

“耐心PATIENCE”

Prevention 预防疾病

Anti–aging 对抗衰老

Treatment 治疗疾病

Interest 有趣好玩

Exercise 锻炼呼吸

Necessity 必需手段

Communication 沟通教育

Evaluation 评估评估

东莞市人民医院护理部在多年使用呼吸训练器（三球仪）的基础上，专门制作了下方的教育视频，为大家介绍呼吸训练器（三球仪）的锻炼方法和注意事项等。请在医护人员的指导下，学习和使用呼吸训练器（三球仪）。

深呼吸训练器的使用视频链接：https://v.qq.com/x/page/l0820it2l65.html

755 Views

伤口世界

电子邮件地址该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Latest from 伤口世界

K2 Content

Diabetes remission in the real world 2024-09-20 00:00

Pam Brown

GP in Swansea

Citation: Brown P (2024) Diabetes Distilled: Diabetes remission in the real world. Diabetes & Primary Care 26: 145–7

Diabetes remission is achievable at scale in the real world, according to early results from the NHS Type 2 Diabetes Path to Remission programme published in Lancet Diabetes & Endocrinology. Of 7540 people referred to the programme between September 2020 and December 2022, a total of 1740 started the total diet replacement section of the programme before January 2022, and 960 (55%) completed the programme. Mean weight loss for the 1710 who started the programme and had follow-up data available was 9.4 kg (8.3%), with a mean weight loss of 10.3 kg (9.3%) among the 945 who completed the programme. Amongst the 945 who completed the programme and had two HbA1c measurements, 32% achieved remission, with mean weight loss of 15.9 kg (14.4%), while overall 27% of those who started the programme achieved remission regardless of whether they completed. Remission rates are lower than in trials such as DiRECT and DIADEM-I, despite similar levels of weight loss. The authors highlight that an additional 17% of participants met the HbA1c targets for remission but continued on metformin and may otherwise have achieved remission. These early results confirm that type 2 diabetes remission is indeed possible at scale in the real world, outside of clinical trials.
Impact of metformin timing on glucose and GLP-1 response 2024-09-19 00:00

Pam Brown GP in Swansea

Citation: Brown P (2024) Diabetes Distilled: Impact of metformin timing on glucose and GLP-1 response. Diabetes & Primary Care 26: 143–4

Glucose-lowering effects in response to normal-release metformin are greater when the drug is given 30 or 60 minutes before, rather than with, food, according to this small study in people with well-controlled type 2 diabetes published in Diabetologia. Endogenous GLP-1 secretion increased when metformin 1000 mg was given 30 or 60 minutes prior to a glucose infusion, whereas there was no increase when the metformin was administered at the same time as the glucose. The results suggest that, if tolerated, administering standard release metformin before meals may lead to improved postprandial glycaemic control.
The importance of getting the correct diabetes diagnosis 2024-09-18 00:00

Jane Diggle Specialist Diabetes Nurse Practitioner, West Yorkshire

Citation: Diggle J (2024) The importance of getting the correct diabetes diagnosis. Diabetes & Primary Care 26: 111–2

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长